banner

CLSA Events

Executive Series: Going Virtual

In the drive to reduce cash burn rates, life science companies are increasingly becoming virtual – owning the IP, but not having any other functional activities in house. They increasingly shed office and laboratory space of their own and depend on outsourcing services from R&D, production, staffing and legal to licensing and taking new products to market. This CEO roundtable discussion will focus on several case studies involving different degrees of virtualization. A discussion with veteran CEOs will contemplate the following questions:

  • Strategy of company development: what factors to consider when contemplating your business model: growing your own company infrastructure vs. going virtual (including degrees of virtualization). Strategy of how to transition from one model to another. Implications for VC’s, board and staff;
  • What competency to maintain internally in order to manage outsourced services correctly;
  • How do you know that you are outsourcing to the right providers and how do you know you are getting the right advice;
  • Company culture: how to preserve it and now not to lose your ability to affect R&D through corporate culture;
  • Role of your clinical advisory board; regulatory, marketing and commercial strategy.

Anchors

Brian Cunningham
Chief Executive Officer, Clerigen Inc.

Steven R. Deitcher, M.D.
President & Chief Executive Officer, Talon Therapeutics, Inc.

Andrew Gengos
President and Chief Executive Officer, Neuraltus Pharmaceuticals, Inc.

Nancy Pecota
Chief Financial Officer, Aradigm Corporation

Jay P. Shepard
President and CEO, NextWave Pharmaceuticals

Moderator

Nina Kjellson
General Partner, InterWest Partners LLC

What: Going Virtual
When: May 18, 2011
5:30pm-7:30pm
Where: OncoMed Pharmaceuticals, Inc.
800 Chesapeake Dr.
Redwood City, CA 94063-4748
Directions
Parking: Complimentary On-Site
Attire: Business attire suggested
Attendance: RSVP by May 15 is required and no registrations will be accepted at the site of the event.
Open to C-Suite Executives of Life Sciences Companies Only.
Cost: BayBio Members – FREE
Non-Members – $75.00